Literature DB >> 10869631

Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center.

S J Freedland1, M Jalkut, F Dorey, M E Sutter, W J Aronson.   

Abstract

OBJECTIVES: To compare the racial differences in clinical and pathologic features between black and white men who underwent radical prostatectomy (RP) in an equal access health care center and to determine whether race is an independent predictor of biochemical recurrence.
METHODS: A retrospective survey of 273 patients (125 black, 148 white) who underwent RP at the West Los Angeles Veterans Affairs Medical Center between 1991 and 1999 was undertaken. Patients were analyzed for racial differences in age at diagnosis, clinical stage, preoperative serum prostate-specific antigen (PSA), and Gleason score of the prostate biopsy specimens. Surgical specimens were studied to determine pathologic stage, Gleason score, incidence of seminal vesicle invasion, positive surgical margins, capsular penetration, and pelvic lymph node involvement. Patients were followed for PSA recurrence (greater than 0.2 ng/mL). Multivariate analysis was used to determine the clinical and pathologic variables that were significant in predicting biochemical recurrence after RP and to determine whether race was an independent predictor of biochemical failure.
RESULTS: No significant differences were found between black and white men in the preoperative factors (clinical stage, age at diagnosis, biopsy Gleason score, and serum PSA) or in the pathologic features of the RP specimens (Gleason score, pathologic stage, incidence of positive surgical margins, capsular penetration, seminal vesicle invasion, or lymph node involvement). In addition, no differences were found between black and white men in the PSA recurrence rates after RP using Kaplan-Meier survival curves (P = 0.651). Multivariate analysis revealed that serum PSA (P = 0.010), biopsy Gleason score (P = 0. 003), younger age (P = 0.010), surgical Gleason score (P = 0.005), and lymph node involvement (P = 0.022) were all independent predictors of biochemical recurrence. Race was not a significant predictor of biochemical failure in multivariate analysis (P = 0. 199).
CONCLUSIONS: In an equal access medical care facility, no differences were evident between black and white men in the preoperative clinical factors or the pathologic features of the RP specimens. In addition, no differences were observed in the PSA recurrence rates after RP. Serum PSA, biopsy Gleason score, younger age, surgical Gleason score, and lymph node involvement were all independent predictors of biochemical recurrence. Race was not an independent predictor of biochemical recurrence.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10869631     DOI: 10.1016/s0090-4295(00)00587-2

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  11 in total

1.  Determinants of mortality following a diagnosis of prostate cancer in Veterans Affairs and private sector health care systems.

Authors:  Vincent L Freeman; Ramon Durazo-Arvizu; Ahsan M Arozullah; LaShon C Keys
Journal:  Am J Public Health       Date:  2003-10       Impact factor: 9.308

2.  Association between race and oncologic outcome following radical prostatectomy for clinically organ-confined prostate cancer: a long-term follow-up study.

Authors:  Erfan Amini; Tracy Campanelli Palmer; Jie Cai; Gary Lieskovsky; Siamak Daneshmand; Hooman Djaladat
Journal:  World J Urol       Date:  2018-03-13       Impact factor: 4.226

3.  Racial disparities in oncologic outcomes after radical prostatectomy: long-term follow-up.

Authors:  Farzana A Faisal; Debasish Sundi; John L Cooper; Elizabeth B Humphreys; Alan W Partin; Misop Han; Ashley E Ross; Edward M Schaeffer
Journal:  Urology       Date:  2014-12       Impact factor: 2.649

Review 4.  Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale.

Authors:  Tiffany A Wallace; Damali N Martin; Stefan Ambs
Journal:  Carcinogenesis       Date:  2011-04-03       Impact factor: 4.944

Review 5.  Racial variation in the pattern and quality of care for prostate cancer in the USA: mind the gap.

Authors:  Daniel A Barocas; David F Penson
Journal:  BJU Int       Date:  2010-06-14       Impact factor: 5.588

6.  Impact of race in a predominantly African-American population of patients with low/intermediate risk prostate cancer undergoing radical prostatectomy within an equal access care institution.

Authors:  David Schreiber; Eric B Levy; David Schwartz; Justin Rineer; Andrew Wong; Marvin Rotman; Jeffrey P Weiss
Journal:  Int Urol Nephrol       Date:  2014-06-27       Impact factor: 2.370

7.  Stage at diagnosis and survival in a multiethnic cohort of prostate cancer patients.

Authors:  Ingrid Oakley-Girvan; Laurence N Kolonel; Richard P Gallagher; Anna H Wu; Anna Felberg; Alice S Whittemore
Journal:  Am J Public Health       Date:  2003-10       Impact factor: 9.308

8.  Re-calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy.

Authors:  Florian R Schroeck; Michael W Kattan; Judd W Moul; William J Aronson; Joseph C Presti; Martha K Terris; Christopher J Kane; Christopher L Amling; Leon Sun; Stephen J Freedland
Journal:  BJU Int       Date:  2009-11-13       Impact factor: 5.588

9.  Patient perspective on watchful waiting/active surveillance for localized prostate cancer.

Authors:  Jinping Xu; Anne Victoria Neale; Rhonda K Dailey; Susan Eggly; Kendra L Schwartz
Journal:  J Am Board Fam Med       Date:  2012 Nov-Dec       Impact factor: 2.657

10.  Effect of socioeconomic factors on long-term mortality in men with clinically localized prostate cancer.

Authors:  Ashutosh K Tewari; Heather Taffet Gold; Raymond Y Demers; Christine Cole Johnson; Rajiv Yadav; Edward H Wagner; Marianne Ulcickas Yood; Terri S Field; George Divine; Mani Menon
Journal:  Urology       Date:  2009-01-23       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.